Arthritis

The oral tyrosine kinase 2 inhibitor deucravacitinib was effective for the treatment of active psoriatic arthritis in a phase II placebo-controlled trial. At week 16, only 31.8% of patients who had been randomized to receive placebo met the 20% response criteria of the American College of Rheumatology (ACR20), compared with […]